Orchid Pharma approves ₹600 crore qualified institutions placement (QIP)

What happened

Orchid Pharma (ORCHPHARMA) told the exchanges on 20 October 2026 at 12:22 PM that it has approved qualified institutions placement (QIP) of ₹600 crore.

How big is it?

At ₹600 crore, the issue is equal to about 13.0% of the company's market value of ₹4,622 crore.

Company snapshot

Orchid Pharma is a small-cap company, with a market value of about ₹4,622 crore.

The stock last traded at ₹911.3, against a 52-week range of ₹480–₹1,143.5 (20.3% below the high).

Before this filing the shares had moved −4.8% over the month and −12.9% over three months. Average daily turnover over the last 20 sessions was about ₹13.48 crore.

Promoters held 69.84% at the end of Q1 FY27. Foreign institutions owned 0.81% and domestic institutions 20.75%.

What history shows

BCEIE's records show 1 previous fund raising filing from the company since May 2026.

Market-wide, 1,619 fund raising filings with an impact score of 50 or more saw an average next-day move of +0.4%, with 48% rising.

Past reactions describe what happened before; they are not a forecast.

What to watch

• How the money raised is used and, for equity instruments, the dilution for existing shareholders.
• 20 October 2026: Board meeting — Fund Raising.

In the news

Recent coverage elsewhere (links open the original publisher):

• Orchid Pharma to allot shares to Dhanuka Labs shareholders — scanx.trade, 18 Oct 2026
• Orchid Pharma vs Nifty 50: 1Y Return +32.39% vs -11.71% — Univest, 9 Oct 2026
• Orchid Pharma Board to Meet October 20 to Evaluate Fundraising Options — Whalesbook, 15 Oct 2026
• Orchid Pharma ORCHPHARMA Q2 FY27 Reg 74(5) Certificate Filed — Kalkine India, 9 Oct 2026
• Orchid Pharma board to meet Oct 20 to evaluate fund raising options — scanx.trade, 15 Oct 2026

Source

• Exchange filing (PDF)